# GPT-5.4 (R2) Review

**Role:** External referee review
**Model:** openai/gpt-5.4
**Paper:** paper.pdf
**Timestamp:** 2026-03-10T13:29:10.525320
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 20283 in / 5254 out
**Response SHA256:** 02e015422e3ecfd5

---

This paper tackles an important policy question with unusually broad data coverage: whether the EU’s 2014 procurement directives increased competition in public procurement. The paper’s strengths are clear: a large administrative dataset, serious attention to modern staggered-adoption DiD concerns, and a commendably non-triumphalist presentation of a mostly null result. The topic is of potential general-interest relevance because procurement is large in fiscal magnitude and the reform was EU-wide.

That said, I do not think the paper is publication-ready in its current form for a top general-interest journal or AEJ: Economic Policy. The central problem is not the null result per se. It is that the paper’s causal interpretation remains substantially weaker than the abstract/introduction suggest. The design uses legal transposition timing as treatment, but the paper itself documents significant pre-trends, acknowledges that transposition timing may be a noisy proxy for implementation, and uses outcomes measured at award rather than tender launch even though many contracts awarded post-transposition were likely initiated under old rules. These issues do not make the paper uninteresting, but they do mean the current version falls short of a credible causal evaluation of the directives.

Below I organize the review around identification, inference, robustness, contribution, interpretation, and a prioritized revision list.

## 1. Identification and empirical design

### A. The main identification strategy is not yet credible enough for the stated causal claim

The paper’s core design exploits cross-country variation in the timing of transposition of Directive 2014/24/EU (Sections 2.3, 4.1). This is a natural starting point, but the identifying assumption is stronger than the paper acknowledges. The key claim is that, conditional on country and quarter fixed effects, transposition timing is unrelated to trends in procurement competition. I do not find that assumption well defended.

Two problems stand out:

1. **The paper directly rejects parallel trends.**  
   In Section 4.4 and elsewhere, the paper reports a pre-trend joint test with \(p<0.001\). That is a major warning sign, not a minor caveat. The manuscript repeatedly argues that “pre-existing trends do not invalidate the null finding.” That is too casual. Violated identifying assumptions do not become irrelevant because the point estimate is near zero. With nonparallel trends, a null estimate can still be biased, especially when treatment is mismeasured or dynamic effects are plausible.

2. **Transposition timing is unlikely to be quasi-random in the relevant sense.**  
   The paper argues that delays reflect “legislative capacity, parliamentary calendars, and political priority” (Section 4.1) and implies these are largely orthogonal to procurement competition. But these same institutional features plausibly correlate with state capacity, quality of procurement administration, digitalization readiness, judicial effectiveness, and broader reform trajectories—all of which can affect bidder participation. Indeed, the paper later explores administrative capacity as a heterogeneity margin, implicitly recognizing that implementation capacity matters. That weakens the case that transposition timing is as-good-as-random.

In short: the manuscript currently has a respectable “event study around staggered legal adoption” design, but not yet a convincingly identified causal estimate of the directives’ effect on competition.

### B. Treatment timing is conceptually misaligned with the mechanism

This is probably the paper’s most important substantive weakness.

The directives changed procurement procedures used when tenders are launched, not just when awards are recorded. Yet the outcomes are built from **contract award notices** and treatment turns on legal transposition from the first full quarter after entry into force (Sections 3.2, 3.3, Appendix A). This creates several timing mismatches:

- A contract **awarded after transposition** may have been **noticed, prepared, and bid under pre-reform rules**.
- Many provisions plausibly phased in at different dates (e-submission, ESPD, lotting, procedural flexibility), so a single transposition date is a coarse proxy.
- The paper includes a processing-days outcome with means around substantial durations, which itself underscores that award timing is not the same as tender-regime timing.

This type of misclassification is likely to attenuate effects toward zero and is especially problematic when the headline result is a null. The paper acknowledges this in the limitations section, but only after drawing strong substantive conclusions. Here it is not a minor limitation; it is central to identification.

At minimum, the paper needs designs that better align treatment with the notice date or procurement start date, or at least exclude a substantial transition window around transposition.

### C. The design window is narrow and potentially weakly informative

Although the sample runs from 2009–2023, all treatment timing variation is concentrated in roughly 2015–2018. After Austria transposes in 2018Q3, there are no untreated controls left. So the identifying variation comes from a short window, even though the panel is long. This matters because:

- secular shifts in procurement reporting, e-procurement infrastructure, or EU monitoring around 2014–2018 can contaminate the comparisons;
- pre-periods are plentiful but may be poor predictors of post-2016 counterfactuals if countries were already on different trajectories;
- the long post-2018 period does not help identify staggered effects once everyone is treated.

The paper should be much more explicit about how much identifying leverage truly comes from 2015–2018 and show cohort-specific support and overlap more transparently.

### D. No-anticipation is not obvious

Section 4.1 assumes no anticipation because firms respond only when they encounter tenders under the new rules. I am not persuaded this is innocuous. Contracting authorities and large firms could plausibly prepare for the reforms before legal transposition, especially because the directive was adopted in 2014 and the deadline was known. Administrative systems, procurement portals, qualification templates, and lotting practices may have adjusted in advance. That would compress differences between “treated” and “untreated” countries and again push estimates toward zero.

The placebo timing tests help somewhat, but shifting all dates back 4 or 8 quarters is not a fully convincing anticipation diagnostic, especially in the presence of observed pre-trends.

### E. Composition and sample selection issues remain under-addressed

The TED sample includes only above-threshold contracts and excludes framework agreements and below-threshold voluntary publication. That is sensible for consistency, but the reform itself may alter what appears in TED, contract packaging, lotting, and whether procurement is above or below threshold. Country-quarter aggregation may also obscure these compositional responses.

The paper mentions sector fixed effects and states results are robust, but this is not enough. CPV fixed effects do not address:
- changes in contract size distribution,
- changes in use of lots versus bundled contracts,
- changes in buyer composition,
- changes in reporting completeness.

Because competition measures are mechanically affected by the composition of observed tenders, this is a first-order issue.

## 2. Inference and statistical validity

### A. The paper does take inference more seriously than many applied papers

This is a strength. The paper reports standard errors for main estimates (Table 3), uses country clustering, presents confidence intervals, and supplements asymptotic inference with wild/bootstrap-style methods and randomization inference (Section 5.4, Appendix C). Given 28 clusters, this is the right instinct.

### B. But the paper still needs a more careful inference framework for the main claims

Several concerns remain.

1. **Cluster count is small for conventional clustered SEs.**  
   Twenty-eight countries is borderline. The paper acknowledges this and reports WCB / pairs bootstrap / RI summaries, which is good. But these alternative inference methods should be integrated into the main tables for the primary outcome, not left as brief robustness bullets.

2. **Randomization inference is oversold.**  
   The RI \(p=0.995\) is described as “strong supplementary evidence” for the null. That is too strong given the identification problems. RI tests whether the observed estimate is unusual under a particular reassignment scheme conditional on the maintained design. It does **not** rescue the design from endogenous timing, treatment mismeasurement, or violated parallel trends. The paper occasionally says this, but elsewhere leans too heavily on RI.

3. **The joint pre-trend test and event-study interpretation are inconsistent.**  
   The text says pre-coefficients “fluctuate around zero without a clear trend,” yet also reports \(p<0.001\) for a joint pre-trend test (Sections 5.2, 4.4). For a top journal, this tension must be confronted more directly. If the pre-period fails the design-based diagnostic, the paper needs either:
   - a redesigned identification strategy, or
   - partial-identification framing rather than standard causal DiD language.

4. **The C-S SME estimate is statistically significant but then discounted informally.**  
   Table 4 reports a negative ATT for SME winner share with CI excluding zero. The paper argues this is driven by one cohort and therefore probably idiosyncratic. That may be true, but then the manuscript should show the full cohort-by-event-time estimates and a principled influence analysis. Right now, the treatment of this result feels ad hoc.

5. **Sample sizes vary nontrivially across outcomes.**  
   The paper reports this clearly, which is good. But for SME and processing-days outcomes, missingness may be endogenous to country and time in ways related to the reform. The manuscript should analyze whether reporting completeness itself changes at transposition. Otherwise null or negative results on SME shares may partly reflect changing reporting regimes.

### C. The staggered DiD implementation is broadly modern, but the paper still relies too much on TWFE for headline interpretation

The manuscript is aware of TWFE problems and reports Callaway–Sant’Anna and Sun–Abraham estimates. That is good. However, the abstract and much of the results section still lead with TWFE magnitudes. Given:
- all units are eventually treated,
- treatment is staggered in a compressed window,
- pre-trends are significant,

the preferred estimates should arguably be the heterogeneity-robust estimands, with TWFE clearly secondary. The current framing still gives the impression that TWFE is the primary design and modern estimators are confirmatory.

## 3. Robustness and alternative explanations

### A. Robustness exercises are extensive, but they do not resolve the core design threats

The paper includes leave-one-out, sector FE, alternative aggregation, placebo dates, Rambachan–Roth bounds, RI, and bootstrap inference. This is better than average. However, many of these exercises are robustness checks around a possibly misaligned treatment definition. If treatment is measured at the wrong time, one can robustly estimate the wrong estimand.

### B. The most important missing robustness checks are timing and implementation checks

For a paper whose mechanism is procedural change, the main omitted analyses are:

1. **Notice-date outcomes instead of award-date outcomes.**  
   Competition is determined at the tender stage. If notice dates are available, treatment should attach to notice dates. If only award notices are available, the authors should at least construct outcomes based on tenders whose notice date post-dates transposition.

2. **Transition-window exclusions / lag structures.**  
   Exclude one to four quarters around transposition; estimate effects beginning only after procurement cycles likely fully reflect the new rules. A null that survives these timing fixes would be much more convincing.

3. **Provision-specific implementation timing.**  
   If e-submission or ESPD had distinct compliance deadlines or uptake measures, exploit those. The current bundled treatment is too coarse relative to the mechanisms emphasized in the introduction.

4. **Reporting-quality outcomes as placebo/diagnostic tests.**  
   Did missingness in bids, SME fields, or award/estimate values change at transposition? If yes, measured outcomes may change for data reasons.

5. **Buyer/procedure/sector heterogeneity linked to theory.**  
   The reform should matter more where procedural frictions are larger: open procedures, SME-intensive sectors, cross-border-prone sectors, high-documentation procurement categories. Administrative-capacity splits are interesting but not the most direct test of mechanism.

### C. Alternative explanations are discussed but not fully disciplined

The paper’s preferred interpretation is that “structural entry barriers dominate procedural ones.” That is plausible, but the evidence is still too indirect. A failure to detect effects using transposition timing could arise from:
- implementation lags,
- partial compliance,
- treatment mismeasurement,
- anticipation,
- outcome mismeasurement,
- low power under heterogeneity,
- aggregation masking sectoral effects.

So the paper should be much more careful in separating:
- “the directives did not improve competition,” from
- “legal transposition timing is not strongly associated with aggregate competition outcomes.”

The current manuscript sometimes acknowledges this distinction, but its discussion and conclusion still lean too far toward the first claim.

## 4. Contribution and literature positioning

### A. The topic is important and the paper could make a useful contribution

The paper’s potential contribution is not that it finds a null per se, but that it assembles EU-wide procurement data and subjects a major regulatory reform to modern quasi-experimental scrutiny. That is worthwhile.

### B. The contribution relative to adjacent work needs sharper calibration

The paper currently claims contributions to procurement, political economy of regulation, and staggered DiD methodology. The last of these is overstated. Applying modern DiD tools is good practice, but not itself a methodological contribution. The paper’s actual contribution is empirical: a large-scale evaluation of EU procurement reform using current methods.

### C. Literature coverage is decent but should be broadened in a few concrete directions

I would suggest adding or engaging more directly with the following strands:

1. **Modern DiD diagnostics / pre-trends / design credibility**
   - Roth (2022), already cited, should be used more substantively rather than as a reason to downplay failed pre-trend tests.
   - Roth, Sant’Anna, Bilinski, Poe (2023), *What’s Trending in Difference-in-Differences?* — useful for framing when trend violations materially alter interpretation.
   - de Chaisemartin and D’Haultfoeuille papers beyond the 2020 reference if relevant to alternative estimands or treatment-effect heterogeneity.

2. **Procurement digitalization / e-procurement**
   The mechanism section emphasizes electronic submission, but the empirical design never really connects to the e-procurement adoption literature. Relevant studies on e-procurement and competition/efficiency should be discussed more directly.

3. **Policy implementation / legal transposition**
   Since the treatment is legal transposition, the paper should engage literature on EU directive transposition and implementation gaps. This matters directly for the external and internal validity of the design.

## 5. Results interpretation and claim calibration

### A. The main conclusions are somewhat over-calibrated relative to the evidence

The strongest defensible claim from the current design is:

> There is no robust evidence that cross-country differences in legal transposition timing of Directive 2014/24/EU generated detectable changes in aggregate country-quarter procurement competition measures in TED.

That is more limited than the paper’s current headline “procedure did not produce competition” framing.

### B. The manuscript handles the null responsibly in some places, but not consistently

To its credit, the paper often says “reduced-form association” and notes transposition may be a noisy proxy. However:
- the title is causal and broad;
- the introduction and conclusion infer that procedural reforms were insufficient;
- the discussion advances structural-barriers explanations more strongly than the evidence warrants.

Those statements may ultimately be right, but the current design does not isolate them cleanly.

### C. The award-ratio result is under-disciplined

Column 4 of Table 3 finds a negative award ratio effect significant at 10%. The paper treats this as suggestive. That is fine, but then it should also acknowledge:
- multiple outcomes are tested;
- award ratio depends on measurement of estimated values, which may vary in quality across countries and over time;
- a result on one secondary outcome amid nulls elsewhere could be noise or composition.

The current discussion gives this result a bit more structural interpretation than is justified.

### D. The paper’s language on precision is inconsistent with its own sensitivity analysis

The text highlights the conventional 95% CI ruling out effects above 2.5 percentage points on the single-bidder share. But the Rambachan–Roth intervals are vastly wider under plausible violations. A paper with rejected pre-trends should not foreground the narrow conventional CI without equal emphasis on the more fragile identification.

## 6. Actionable revision requests

### 1. Must-fix issues before acceptance

#### 1. Rebuild the treatment timing to align with procurement initiation, not award timing
- **Issue:** Treatment is assigned based on legal transposition and outcomes are measured on award notices, even though competition is determined earlier at tender launch.
- **Why it matters:** This likely creates severe attenuation/mismeasurement, especially damaging for a null result.
- **Concrete fix:** Reconstruct the main outcomes using tenders whose **notice date** is post-transposition, or define treatment relative to notice/publication date where available. At minimum, exclude contracts whose notice date predates transposition and implement transition-window exclusions of 1–4 quarters.

#### 2. Address the failed pre-trend diagnostics as a central design problem, not a side note
- **Issue:** The paper reports \(p<0.001\) for pre-trends but still treats the design as broadly causal.
- **Why it matters:** A top journal will not accept a DiD paper that fails its own identifying diagnostic without substantial redesign or reframing.
- **Concrete fix:** Either (i) move to a design with better comparability (e.g., matched/event-specific comparisons, synthetic control style cohort analyses, or differential trend adjustments justified ex ante), or (ii) reframe the paper as partial-identification / reduced-form evidence on transposition timing rather than causal reform effects.

#### 3. Provide implementation evidence beyond legal transposition
- **Issue:** Transposition may be a poor proxy for actual practice change.
- **Why it matters:** Without evidence that procurement procedures changed sharply at transposition, the treatment lacks first-stage credibility.
- **Concrete fix:** Show whether e-submission usage, ESPD-related fields, lot division, procedure types, award criteria, or reporting variables shift at transposition. If there is no first stage in procedural variables, the interpretation should change materially.

#### 4. Make heterogeneity-robust estimators primary and present full design diagnostics
- **Issue:** TWFE remains the headline despite compressed staggered timing and eventual universal treatment.
- **Why it matters:** In this setting, the estimand and identifying comparisons need to be transparent.
- **Concrete fix:** Lead with C-S / Sun-Abraham results; present cohort sizes, support windows, group-time ATTs, and sensitivity of aggregate estimates to cohort omission.

#### 5. Analyze reporting completeness and sample composition as outcomes
- **Issue:** Missing SME status, bid counts, and other fields may vary with reform and country.
- **Why it matters:** Apparent nulls or negatives may reflect changes in reporting rather than market behavior.
- **Concrete fix:** Estimate event studies for missingness rates, contract counts, average estimated values, lotting, buyer types, and procedure composition.

### 2. High-value improvements

#### 6. Strengthen the theory-to-empirics mapping
- **Issue:** The paper argues about procedural vs structural barriers, but the empirical analysis does little to isolate where procedural frictions should matter most.
- **Why it matters:** Mechanism-consistent heterogeneity would greatly improve interpretability even if average effects remain null.
- **Concrete fix:** Examine effects by sector, procedure type, contract size, buyer type, cross-border-prone sectors, and baseline SME intensity.

#### 7. Clarify the estimand induced by weighting
- **Issue:** Regressions weight by contract counts, shifting emphasis toward large markets and high-volume quarters.
- **Why it matters:** The paper alternates between country-level policy claims and contract-level average effects.
- **Concrete fix:** Report weighted and unweighted estimates side by side and state clearly whether the estimand is the average effect on contracts or on country-quarters.

#### 8. Reassess the SME result systematically
- **Issue:** The significant negative C-S SME estimate is dismissed informally as cohort-driven.
- **Why it matters:** This is the main non-null result besides award ratio and deserves disciplined analysis.
- **Concrete fix:** Show cohort-specific SME ATTs, leave-one-cohort-out aggregation, and whether reporting completeness or composition changed disproportionately for the 2017Q1 cohort.

#### 9. Report inference from small-cluster methods in the main tables
- **Issue:** Main tables show only clustered SEs.
- **Why it matters:** With 28 clusters, readers need the main inferential object to reflect finite-sample concerns.
- **Concrete fix:** Add wild cluster bootstrap or RI p-values/CIs for primary outcomes directly in the main results table.

### 3. Optional polish

#### 10. Recalibrate the title and abstract if the design remains unchanged
- **Issue:** The current title is stronger than the identification warrants.
- **Why it matters:** Reader expectations and evidentiary strength should match.
- **Concrete fix:** Consider a title emphasizing “transposition timing” or “legal implementation” rather than “procedure” broadly.

#### 11. Tighten claims about precision
- **Issue:** Conventional CIs are emphasized more than sensitivity-robust intervals.
- **Why it matters:** This overstates what the data can rule out.
- **Concrete fix:** Put conventional and Rambachan–Roth intervals side by side in the main text for the primary outcome.

#### 12. Sharpen contribution statements
- **Issue:** The methodological contribution is overstated.
- **Why it matters:** Top-journal positioning should be precise.
- **Concrete fix:** Present the paper as an empirical evaluation using modern tools, not as a methodological frontier contribution.

## 7. Overall assessment

### Key strengths
- Important policy question with broad relevance.
- Impressive EU-wide data assembly and clear institutional setup.
- Serious attempt to use modern staggered-adoption methods rather than naïve TWFE alone.
- Willingness to report null findings and acknowledge some limitations.
- Multiple robustness and inference checks, better than typical practice.

### Critical weaknesses
- Identification is not convincing in its current form due to significant pre-trends and likely non-random transposition timing.
- Treatment timing is poorly aligned with the mechanism because outcomes are measured at award while reform affects tender procedures.
- Legal transposition is an uncertain proxy for actual implementation; no first-stage evidence is shown.
- The paper over-interprets null reduced-form evidence as evidence that procedural reform was ineffective.
- Some non-null findings (SME, award ratio) are handled inconsistently.

### Publishability after revision
There is a potentially publishable paper here, but not yet in current form. The key question is whether the authors can convert this from a suggestive transposition-timing study into a more credible implementation-timing evaluation, or else substantially reframe the contribution around limits of legal transposition as a proxy for reform. If the timing and first-stage issues can be addressed well, the paper could become a useful contribution. Without that, it is unlikely to clear the bar of a top field or general-interest journal.

DECISION: MAJOR REVISION